Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Down 70.0% in June

Posted by George Bondi on Jul 12th, 2026

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP – Get Free Report) saw a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 101,413 shares, a decline of 70.0% from the June 15th total of 337,919 shares. Based on an average trading volume of 158,411 shares, the days-to-cover ratio is currently 0.6 days. Approximately 8.3% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aspire Biopharma in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Aspire Biopharma currently has a consensus rating of “Sell”.

Get Our Latest Report on Aspire Biopharma

Aspire Biopharma Stock Performance

NASDAQ ASBP traded down $0.06 on Friday, hitting $6.01. 22,926 shares of the stock were exchanged, compared to its average volume of 761,110. Aspire Biopharma has a 52-week low of $3.31 and a 52-week high of $1,050.36. The firm has a market capitalization of $7.81 million, a P/E ratio of -0.05 and a beta of 0.15. The stock has a fifty day moving average price of $5.73 and a two-hundred day moving average price of $36.86.

Aspire Biopharma (NASDAQ:ASBP – Get Free Report) last announced its earnings results on Friday, May 15th. The company reported ($20.57) earnings per share for the quarter. The firm had revenue of $0.03 million for the quarter.

Institutional Trading of Aspire Biopharma

Several institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its position in shares of Aspire Biopharma by 2,252.1% during the fourth quarter. Jane Street Group LLC now owns 688,143 shares of the company’s stock valued at $91,000 after buying an additional 658,886 shares during the period. XTX Topco Ltd raised its holdings in shares of Aspire Biopharma by 853.2% in the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after buying an additional 237,620 shares during the period. Finally, CIBC Bancorp USA Inc. bought a new stake in shares of Aspire Biopharma during the 3rd quarter worth approximately $28,000. Institutional investors own 19.17% of the company’s stock.

About Aspire Biopharma

(Get Free Report)

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.